SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

PF-08046040 is under clinical development by Pfizer and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Interesting trends were observed in the subgroup analyses of the phase 3 uproleselan study in relapsed or refractory acute ...

Community Ambulance worked with Candlelighters Childhood Cancer Foundation to deliver holiday joy to a 1-year-old born with ...

Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...

Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive an allogeneic hematopoietic stem cell transplant for acute myeloid. However ...

The US Acute Myeloid Leukemia (AML) Market is poised for robust growth, driven by advancements in treatment approaches, increased healthcare expenditures, substantial investments in Research and ...

This year’s most-viewed articles and videos on myelodysplastic syndromes (MDS) explored patient quality of life, risk factors ...

One common form of leukemia is acute myeloid leukemia (AML), characterized by a degradation of early blood cell precursors, ... Patients with acute myeloid leukemia who have lower education levels ...

The family drama surrounding fallen Syrian dictator Bashar al-Assad took a new twist Thursday as his wife was reported to be ...